Table 2.
Sample demographics and clinical data for human cases used in the quantitative polymerase chain reaction analysis of VEGF
| Values (mean ± SEM) | Healthy controls | Non-dyskinetic Parkinson’s disease | Dyskinetic Parkinson’s disease | P-value (statistical test used) |
|---|---|---|---|---|
| n (all male) | 18 | 12 | 11 | |
| Age at death | 72.2 ± 7.9 | 74.3 ± 5.0 | 75.9 ± 7.3 | 0.3 (ANOVA) |
| Post-mortem delay (h) | 16.4 ± 4.8 | 16.4 ± 6.0 | 15.0 ± 5.2 | 0.9 (ANOVA) |
| Age at Parkinson’s disease onset (years) | NA | 68.2 ± 7.7 | 57.8 ± 8.9 | 0.6 (t-test, t = −2.7) |
| Parkinson’s disease duration (years) | NA | 7.8 ± 5.1 | 16.5 ± 8.4# | 0.02 (t-test, t = 2.8) |
| Years of l-dopa use | NA | 4.0 ± 3.3 | 10.2 ± 5.6 | 0.1 (t-test, t = 2.7) |
| Lifetime l-dopa amount (g) | NA | 768.8 ± 965.5 | 2707 ± 2436# | 0.004 (t-test, t = 2.3) |
| VEGF messenger RNA levels/normalization controls (average of the two primers used) | 0.865 ± 0.085 | 0.967 ± 0.157 | 1.475 ± 0.233*,# | 0.016 (ANOVA) |
NA = not applicable.
*P < 0.05 vs healthy controls, # versus non-dyskinetic Parkinson's disease patients.